These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15492973)

  • 1. Outcomes associated with hypogonadism in women with chronic kidney disease.
    Weisinger JR; Bellorin-Font E
    Adv Chronic Kidney Dis; 2004 Oct; 11(4):361-70. PubMed ID: 15492973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
    Toussaint ND; Elder GJ; Kerr PG
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone health in chronic kidney disease-mineral and bone disease.
    Gal-Moscovici A; Sprague SM
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):27-36. PubMed ID: 17200041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexual function in chronic kidney disease.
    Anantharaman P; Schmidt RJ
    Adv Chronic Kidney Dis; 2007 Apr; 14(2):119-25. PubMed ID: 17395114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protecting the endothelium: a new focus for management of chronic kidney disease.
    Diaz-Buxo JA; Woods HF
    Hemodial Int; 2006 Jan; 10(1):42-8. PubMed ID: 16441826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease in postmenopausal women.
    Suzuki H; Kondo K
    Hypertens Res; 2012 Feb; 35(2):142-7. PubMed ID: 21900940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes associated with hypogonadism in men with chronic kidney disease.
    Palmer BF
    Adv Chronic Kidney Dis; 2004 Oct; 11(4):342-7. PubMed ID: 15492970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for bisphosphonates in chronic kidney disease?
    Miller PD
    Semin Dial; 2007; 20(3):186-90. PubMed ID: 17555478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
    Rutkowski M; Mann W; Derose S; Selevan D; Pascual N; Diesto J; Crooks P
    Am J Kidney Dis; 2009 Mar; 53(3 Suppl 3):S86-99. PubMed ID: 19231766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients.
    Fernandez-Fresnedo G; Rodrigo E; de Francisco AL; de Castro SS; Castañeda O; Arias M
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S246-9. PubMed ID: 17130269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease and chronic kidney disease: insights and an update.
    Best PJ; Reddan DN; Berger PB; Szczech LA; McCullough PA; Califf RM
    Am Heart J; 2004 Aug; 148(2):230-42. PubMed ID: 15308992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rational guide to reducing fracture risk in dialysis patients.
    Toussaint ND; Elder GJ; Kerr PG
    Semin Dial; 2010; 23(1):43-54. PubMed ID: 20331818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease.
    Kendrick J; Chonchol MB
    Nat Clin Pract Nephrol; 2008 Dec; 4(12):672-81. PubMed ID: 18825155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary osteoporosis UPDATE. Bone disease with decreased kidney function].
    Okuno S; Ishimura E
    Clin Calcium; 2010 May; 20(5):655-62. PubMed ID: 20445276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypogonadism in men with chronic kidney disease.
    Johansen KL
    Adv Chronic Kidney Dis; 2004 Oct; 11(4):348-56. PubMed ID: 15492971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs.
    Nogueira J; Weir M
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):766-85. PubMed ID: 17699494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Justification for the use of HRT in the long-term prevention of osteoporosis.
    Stevenson JC
    Maturitas; 2005 Jun; 51(2):113-26. PubMed ID: 15917151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease.
    Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
    Nephrol Dial Transplant; 2008 Feb; 23(2):586-93. PubMed ID: 17933842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease.
    Roberts MA; Hare DL; Ratnaike S; Ierino FL
    Am J Kidney Dis; 2006 Sep; 48(3):341-60. PubMed ID: 16931208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.